NeuACT, a Phase II trial of DN24-02 in Patients with Surgically Resected HER2+ Urothelial Cancer

Summary of SUO 2013 poster, "NeuACT, a Phase 2 Randomized, Open-label Trial of DN24-02 in Patients with Surgically Resected HER2+ Urothelial Cancer: Updated Analysis of Product Parameters, HER2 Expression and Safety"

Leonard G. Gomella, MD, FACS
Thomas Jefferson University Hospital

Click HERE to read the abstract and view the poster

Click HERE to read a report from this session by the Fox Chase Cancer Center team

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe